Dry Eye

Patient quality of life has been shown to be severely impaired by the associated ocular surface symptoms, so treatment aims for symptomatic relief and prevention of further damage to the ocular surface.

A look back on what's happened in optometry during the week of Jan. 1-Jan. 5, 2023.

Diagnosing and treating dry eye and meibomian gland dysfunction can be the foundation for practice growth—and patient satisfaction.

Marc R. Bloomenstein, OD, FAAO, gives an overview of the SAHARA study.

Selina McGee, OD, FAAO, founder and owner of BeSpoke Vision in Edmond, Oklahoma, shares key takeaways from her discussion, "Pro- and Anti-Inflammatory Cytokine Levels in Tears of Dry Eye Subjects,“ which she presented during the 2022 American Academy of Optometry meeting in San Diego.

Pinakin Davey, PhD, OD, FAAO, gives key highlights from his AAOpt 2022 presentation, "Management of digital eye strain: comprehensive strategy and nutritional approach."

Jim Sluck, VP of Marketing for Sight Sciences' TearCare, shares the impetus behind the company's fair access campaign.

Nidhi Rana, OD, discusses key highlights from her AAOpt 2022 presentation on pediatric red eye.

Derek Cunningham, OD, FAAO, gives key takeaways from his AAOpt 2022 discussion, "Back to the basics: The importance of treating inflammation AND obstruction for dry eye."

Jeff Nau, PhD, president and CEO of Oyster Point Pharma shares an update on the company's Tyrvaya product.

When combined, intense pulsed light and low-level light therapy—both of which have roots in dermatology—create a synergistic effect that treat dry eye more effectively than one therapy alone.

Modern technology enables early detection, individualized solutions.

Preservative-free eye drops offer benefits for ocular health.

Katherine M. Mastrota, OD, FAAO, advises on how to diagnosis this condition and not fall prey to a “knee-jerk” dry eye diagnosis.

When oral acne treatments lead to ocular surface disease, the solution lies in office-based therapies.

Janelle Davison, OD, shares highlights from her VEW 2022 presentation, "Intersection of dry eye and beauty: design, build and brand a profitable dry eye spa."

Azura has secured funding to support its 2-stage study evaluating the safety, tolerability, and efficacy of AZR-MD-001, its leading candidate, for patients with contact lens discomfort who show signs of meibomian gland dysfunction.

Bausch + Lomb and Novaliqu announced that the FDA has accepted its New Drug Application for NOV03, an investigational treatment for dry eye disease associated with meibomian gland dysfunction.

FDA-approved steroid offers short-term relief for ocular surface inflammation.

Ensure successful symptoms management with your patients.

Latest transaction, totaling approximately $770 million, adds key commercial products and clinical/preclinical product candidates in the pipeline.

Optometry Times' editor Kassi Jackson speaks with Lauretta Justin, OD, founder of Optometry Divas, and Lisa Hornick, OD, recipient of Optometry Divas' Thought Leader of the Year 2022 award.

COMET-3 is the second of 3 studies in the AR-15512 Registrational Phase 3 Program, which is slated for completion by 2023.

One OD shares his experience launching a successful social media campaign for Dry Eye Awareness month—and offers 3 tips for crafting a message to capture an audience's attention.

Contact lenses soaked in melatonin analogs may be able to address aqueous tear deficient dry eye disease, researchers say.

Lindsay A. Sicks, OD, FAAO, shares her number 1 tip for managing dry eye.

Case gives new perspective on subconjunctival hemorrhages

The first-of-its-kind alliance and latest phase of AOA's national public awareness campaign focuses on the effects of extended time on digital devices and its impact on eye health.

Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, shares his number 1 tip for managing dry eye.

Best practices to help patients enjoy their trip to the fullest.